StockNews.com upgraded shares of InfuSystem (NYSE:INFU – Free Report) from a buy rating to a strong-buy rating in a research note published on Friday.
InfuSystem Trading Up 0.9 %
NYSE INFU opened at $6.46 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.07 and a quick ratio of 1.64. The company has a market cap of $137.57 million, a P/E ratio of -646,000.00 and a beta of 1.46. InfuSystem has a 52 week low of $5.74 and a 52 week high of $10.99.
InfuSystem (NYSE:INFU – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The firm had revenue of $33.70 million for the quarter. InfuSystem had a return on equity of 0.70% and a net margin of 0.28%.
Institutional Inflows and Outflows
InfuSystem Company Profile
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Featured Stories
- Five stocks we like better than InfuSystem
- Stock Sentiment Analysis: How it Works
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How Investors Can Find the Best Cheap Dividend Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What Are Dividend Challengers?
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.